Suppliers and packagers for generic pharmaceutical drug: CABERGOLINE

CABERGOLINE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Amneal	CABERGOLINE	cabergoline	TABLET;ORAL	218618	ANDA	A-S Medication Solutions	50090-7642-0	8 TABLET in 1 BOTTLE (50090-7642-0)	2024-10-03
Amneal	CABERGOLINE	cabergoline	TABLET;ORAL	218618	ANDA	Amneal Pharmaceuticals NY LLC	69238-2693-1	8 TABLET in 1 BOTTLE (69238-2693-1)	2024-10-03
Ingenus Pharms Llc	CABERGOLINE	cabergoline	TABLET;ORAL	204735	ANDA	A-S Medication Solutions	50090-5834-0	8 TABLET in 1 BOTTLE (50090-5834-0)	2018-08-09
Ingenus Pharms Llc	CABERGOLINE	cabergoline	TABLET;ORAL	204735	ANDA	Ingenus Pharmaceuticals, LLC	50742-118-08	8 TABLET in 1 BOTTLE (50742-118-08)	2018-08-09
Ivax Sub Teva Pharms	CABERGOLINE	cabergoline	TABLET;ORAL	077750	ANDA	Teva Pharmaceuticals USA, Inc.	0093-5420-88	1 BOTTLE in 1 CARTON (0093-5420-88) / 8 TABLET in 1 BOTTLE	2007-03-07
Ivax Sub Teva Pharms	CABERGOLINE	cabergoline	TABLET;ORAL	077750	ANDA	A-S Medication Solutions	50090-3157-0	1 BOTTLE in 1 CARTON (50090-3157-0) / 8 TABLET in 1 BOTTLE	2007-03-07

Cabergoline API: Key Global Suppliers and Manufacturing Landscape

Last updated: February 19, 2026

This report details the primary global suppliers of cabergoline active pharmaceutical ingredient (API), their manufacturing capabilities, and regulatory standing. The market is characterized by a limited number of established manufacturers, with a focus on regulatory compliance and consistent quality for this niche therapeutic.

Who Are the Leading Global Suppliers of Cabergoline API?

The global supply of cabergoline API is concentrated among a few key manufacturers, primarily located in India and Europe. These suppliers are critical for pharmaceutical companies developing and manufacturing finished dosage forms of cabergoline, a dopamine agonist used to treat hyperprolactinemia and Parkinson's disease.

Key Cabergoline API Suppliers:

• Abbott Laboratories (now AbbVie Inc.): While Abbott developed cabergoline (brand name Dostinex), its primary role today is in the finished product. API manufacturing may be contracted or handled by specific divisions. Historical leadership in the product’s development is significant.
• Taj Pharmaceuticals Ltd.: Based in India, Taj Pharmaceuticals is a prominent supplier of various APIs, including cabergoline. They operate multiple manufacturing facilities and focus on cGMP compliance.
• Sun Pharmaceutical Industries Ltd.: Another major Indian pharmaceutical company, Sun Pharma manufactures a wide range of APIs and finished formulations. Cabergoline is among their offerings, supported by their extensive R&D and manufacturing infrastructure.
• Teva Pharmaceutical Industries Ltd.: A global leader in generic pharmaceuticals, Teva is a significant player in API production. They have the capacity and regulatory approvals to supply cabergoline to international markets.
• Intas Pharmaceuticals Ltd.: Headquartered in India, Intas Pharmaceuticals is a vertically integrated pharmaceutical company involved in API manufacturing. They supply cabergoline to various markets.
• Divi's Laboratories Limited: While not explicitly listed for cabergoline in all public databases, Divi's is a major global API manufacturer known for its expertise in complex synthesis and large-scale production. Their portfolio is broad, and they are a potential supplier for this API.
• European API Manufacturers: Several smaller, specialized European chemical manufacturers may also produce cabergoline API, often catering to specific regional markets or adhering to strict European GMP standards. These entities are less publicly prominent but contribute to the overall supply chain.

The selection of a reliable API supplier involves rigorous due diligence, focusing on their regulatory history, quality control systems, production capacity, and supply chain security.

What Are the Manufacturing and Regulatory Considerations for Cabergoline API?

The manufacturing of cabergoline API requires adherence to stringent Good Manufacturing Practices (GMP) to ensure product safety, efficacy, and purity. Regulatory oversight by agencies like the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others is paramount.

Key Manufacturing Aspects:

• Synthesis Route: Cabergoline synthesis is a multi-step chemical process. Manufacturers must optimize these steps for yield, purity, and cost-effectiveness while minimizing impurities. Common synthetic approaches involve intermediates derived from ergot alkaloids.
• Quality Control: Comprehensive analytical testing is performed at various stages of production, including raw material inspection, in-process controls, and final API release testing. This includes assays for potency, impurity profiling (related substances, residual solvents), and physical characteristics (particle size, polymorphism).
• Stability Studies: API manufacturers conduct rigorous stability studies under various conditions (temperature, humidity, light) to establish shelf-life and recommended storage conditions. This data is crucial for the drug product manufacturer.
• Impurity Control: Identification and quantification of process-related impurities and degradation products are critical. Limits are set based on ICH guidelines and regulatory expectations. Specific impurities, such as isomers or degradation products formed under stress conditions, require careful monitoring.
• cGMP Compliance: Facilities must operate under current Good Manufacturing Practices (cGMP). This involves robust quality management systems, validated processes, qualified equipment, trained personnel, and detailed documentation.
• Scale-Up Capabilities: Manufacturers must demonstrate the ability to scale production from laboratory to commercial volumes while maintaining consistent quality. This involves process validation at different scales.

Regulatory Landscape:

• Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory authorities (e.g., FDA in the U.S., EDQM in Europe). A DMF contains confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of drugs. This allows drug product manufacturers to reference the DMF in their regulatory submissions without disclosing proprietary information.
• Certificate of Suitability (CEP): In Europe, a Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) is often required. A CEP demonstrates that the quality of an API is suitably controlled by the monograph(s) of the European Pharmacopoeia.
• FDA Inspections: API manufacturing sites supplying the U.S. market are subject to FDA inspections to verify cGMP compliance. Successful inspection outcomes are critical for API approval.
• EMA Inspections/Certifications: Similar inspection and certification processes are conducted by EMA and national competent authorities within the EU.
• Other Regulatory Agencies: Manufacturers supplying markets in Japan, Canada, Australia, and other regions must comply with the specific regulatory requirements of those countries.
• ICH Guidelines: International Council for Harmonisation (ICH) guidelines (e.g., Q7 for API GMP, Q3 for impurities) form the basis for global regulatory expectations.

The availability of a consistent, high-quality cabergoline API with comprehensive regulatory documentation is essential for pharmaceutical companies seeking to market generic or new cabergoline-containing drug products.

What is the Global Market Size and Growth Outlook for Cabergoline API?

The market for cabergoline API is relatively niche, driven by its specific therapeutic applications. Market size is influenced by the prevalence of hyperprolactinemia and Parkinson's disease, the availability of generic alternatives, and the development of new treatment protocols.

Market Dynamics:

• Prevalence of Conditions: The demand for cabergoline is directly linked to the diagnosis rates of hyperprolactinemia (including prolactinomas) and its use as an adjunct therapy in Parkinson's disease.
• Generic Competition: The patent expiry of originator brand cabergoline has led to increased competition from generic manufacturers. This typically increases the overall volume of API required but can put pressure on API pricing.
• Therapeutic Advancements: While cabergoline is an established drug, ongoing research into dopamine agonists or alternative treatments for its target conditions can influence future demand.
• Geographic Distribution: Demand is highest in developed markets with advanced healthcare infrastructure and established diagnostic capabilities, such as North America and Europe, followed by emerging markets in Asia and Latin America.
• API Pricing: API pricing is influenced by manufacturing costs, regulatory compliance expenses, supply and demand dynamics, and the competitive landscape among API manufacturers.
• Contract Manufacturing: Pharmaceutical companies may choose to contract manufacture cabergoline API to manage costs, leverage specialized expertise, or ensure supply chain resilience.

Growth Projections:

Specific market size and growth figures for cabergoline API are not as widely published as for broader therapeutic categories. However, general market trends for dopamine agonists and APIs for neurological and endocrine disorders suggest a stable to moderate growth trajectory.

• CAGR Estimates: Industry reports focusing on the broader neurological or endocrine API markets project Compound Annual Growth Rates (CAGRs) generally ranging from 4% to 7% over the next five to seven years. Cabergoline's specific segment likely aligns with these broader trends, potentially at the lower to mid-end of this range due to its targeted application.
• Key Drivers: The increasing aging population globally, which is associated with a higher incidence of neurodegenerative diseases like Parkinson's, is a key driver. Improved diagnosis of hyperprolactinemia also contributes to sustained demand.
• Challenges: Market growth can be tempered by the development of newer therapeutic agents that offer improved efficacy or safety profiles, or by stringent pricing regulations in various healthcare systems.

The market for cabergoline API is characterized by established suppliers and a steady demand, with growth primarily driven by an aging global population and improved disease diagnosis rather than rapid expansion into new therapeutic areas.

What Are the Key Challenges and Opportunities for Cabergoline API Suppliers?

Suppliers of cabergoline API face a competitive landscape and evolving regulatory requirements. Opportunities exist for those who can demonstrate consistent quality, regulatory expertise, and reliable supply chains.

Challenges:

• Intense Price Competition: The presence of multiple generic API manufacturers, particularly from India and China, leads to significant price pressure. Suppliers must optimize their manufacturing processes to remain cost-competitive.
• Stringent Regulatory Scrutiny: Regulatory bodies worldwide are continuously enhancing their scrutiny of API manufacturing. Suppliers must maintain robust quality systems and be prepared for frequent inspections. Any regulatory non-compliance can lead to significant business disruptions and loss of market access.
• Supply Chain Disruptions: Global events, such as pandemics or geopolitical instability, can disrupt raw material sourcing and logistics, impacting API production and delivery timelines. Maintaining resilient supply chains is crucial.
• Quality Assurance Demands: Pharmaceutical companies procuring cabergoline API demand high levels of quality assurance, including comprehensive impurity profiling, validated analytical methods, and detailed batch records. Meeting these demands requires continuous investment in quality control infrastructure.
• Patent Expirations and Genericization: While the patent expiry of the originator product has opened the market to generics, it also means that the overall market value for API might not grow as rapidly as it did for the branded product.

Opportunities:

• Emerging Markets: As healthcare access improves in emerging economies, the demand for essential medicines like cabergoline is expected to rise. Suppliers with a global regulatory footprint can capitalize on these opportunities.
• Vertical Integration: Companies that can control their raw material supply chains or offer integrated API and finished dosage form services may gain a competitive advantage.
• Specialized Manufacturing Expertise: Cabergoline synthesis is complex. Suppliers with proven expertise in difficult chemical synthesis and high-purity API production can command a premium and secure long-term contracts.
• Regulatory Excellence: Suppliers who consistently maintain high regulatory standards and can readily provide comprehensive documentation (DMFs, CEPs) are highly valued by drug product manufacturers seeking expedited regulatory approvals.
• Focus on Niche Applications: While its primary uses are established, ongoing research might uncover new therapeutic applications for cabergoline or related ergoline derivatives, creating new market opportunities for API suppliers.
• Strategic Partnerships: Forming strategic partnerships with generic drug manufacturers or even specialty pharmaceutical companies can provide stable, long-term supply agreements.

Navigating these challenges and capitalizing on opportunities requires a strategic focus on operational efficiency, unwavering commitment to quality and regulatory compliance, and adaptability to market dynamics.

Key Takeaways

• The global cabergoline API supply chain is concentrated among a limited number of established manufacturers, primarily in India and Europe.
• Key suppliers include Taj Pharmaceuticals, Sun Pharmaceutical Industries, and Teva Pharmaceutical Industries, alongside potential contributions from specialized European manufacturers.
• Manufacturing requires strict adherence to cGMP standards, robust quality control, and comprehensive regulatory documentation, including DMFs and CEPs.
• The market size is niche, driven by the prevalence of hyperprolactinemia and Parkinson's disease, with stable to moderate growth projected, influenced by aging populations and improved diagnostics.
• Challenges for suppliers include intense price competition and stringent regulatory scrutiny, while opportunities lie in emerging markets, specialized manufacturing expertise, and demonstrating consistent regulatory excellence.

Frequently Asked Questions

What is the typical shelf life for cabergoline API?

The typical shelf life for cabergoline API, when stored under recommended conditions (e.g., protected from light and moisture), is generally between two to three years. This is determined by rigorous stability studies conducted by the API manufacturer as per ICH guidelines.

Are there specific impurities that regulatory agencies scrutinize heavily in cabergoline API?

Yes, regulatory agencies heavily scrutinize process-related impurities and potential degradation products. For cabergoline, particular attention is paid to isomers, residual solvents from the synthesis process, and any impurities that could arise from oxidation or degradation of the ergoline structure. Manufacturers must demonstrate control over these impurities within ICH-defined limits.

How does the regulatory status of an API supplier impact its ability to serve global markets?

The regulatory status is critical. A supplier's ability to consistently meet cGMP standards and pass inspections from agencies like the FDA, EMA, and others directly dictates their access to major pharmaceutical markets. A strong regulatory history, evidenced by approved DMFs and CEPs, is a prerequisite for pharmaceutical companies to include the API in their drug product applications.

What is the primary difference in API manufacturing standards between India and Europe?

While both regions adhere to cGMP principles, European manufacturers often emphasize proprietary process development and may be subject to stricter environmental regulations. Indian manufacturers are renowned for their large-scale, cost-effective production and have significantly advanced their quality systems to meet international standards, often holding numerous FDA and EMA approvals. The core principles of quality and safety are universal, but the nuances in regulatory enforcement and specific manufacturing practices can differ.

Can a pharmaceutical company use multiple suppliers for cabergoline API for a single drug product?

Yes, pharmaceutical companies can and often do qualify multiple suppliers for critical APIs like cabergoline to ensure supply chain security and mitigate risks associated with single-source dependency. Each supplier must undergo the same rigorous qualification process, and their API must meet all the same quality specifications.